(Reuters) - Array BioPharma Inc said it was abandoning a late-stage study testing its experimental drug on ovarian cancer patients, after an interim analysis showed the trial would likely fail.
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire